Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ID93 (Access to Advanced Health Institute)
- Development stage
- Unknown
- Lead developer
- Quratis
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ID93 is a recombinant protein subunit vaccine candidate designed for the prevention and treatment of tuberculosis. It consists of a fusion protein comprising four *Mycobacterium tuberculosis* (Mtb) antigens: Rv2608, Rv3619, Rv3620, and Rv1813. These antigens represent different stages of the Mtb life cycle, including virulence factors and proteins expressed during latency. The vaccine is typically formulated with a Toll-like receptor 4 (TLR4) agonist adjuvant, such as Glucopyranosyl Lipid A (GLA) in either a stable emulsion (GLA-SE) or a liposomal formulation (GLA-LSQ, also known as AP10-602). Originally developed by the Infectious Disease Research Institute (IDRI), now known as the Access to Advanced Health Institute (AAHI), with support from the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine is also being developed by Quratis under the name QTP101. It aims to induce a robust Th1-polarized immune response to provide protection against both active and latent tuberculosis.
- Other names
- ID93 + GLA-SEID93 + AP10-602ID93 + GLA-LSQID93/GLA-SEID93/GLA-LSQ
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on ID93 (Access to Advanced Health Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ID93 (Access to Advanced Health Institute).